CureVac Long Term Debt 2021-2021 | CVAC
CureVac long term debt from 2021 to 2021. Long term debt can be defined as the sum of all long term debt fields.
| CureVac Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2021 | $29 |
| 2020 | $31 |
| 2019 | $ |
| CureVac Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2021-12-31 | $29 |
| 2020-12-31 | $31 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $3.621B | $0.116B |
| CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $162.107B | 9.86 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.761B | 16.99 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.111B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.648B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.770B | 7.57 |
| Arcus Biosciences (RCUS) | United States | $1.376B | 34.89 |
| Myovant Sciences (MYOV) | United Kingdom | $1.033B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.397B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.345B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.157B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.110B | 22.60 |
| SQZ Biotechnologies (SQZ) | United States | $0.100B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
